Orally disintegrable tablets

DC CAFC

US 6,328,994 B1
Filed: 08/04/1999
Issued: 12/11/2001
Est. Priority Date: 05/18/1998
Status: Expired due to Term

- Alert
- Pin

Associated Cases

Associated Defendants

First Claim

Patent Images

1. An orally disintegrable tablet which comprises(i) fine granules having an average particle diameter of 400 μ

m or less, which fine granules comprise a composition coated by an enteric coating layer comprising a first component which is an enteric coating agent and a second component which is a sustained-release agent, said composition having 10 weight % or more of an acid-labile physiologically active substrate that is lansoprazole and (ii) an additive wherein said tablet having a hardness strength of about 1 to about 20 kg, is orally disintegrable.

View all claims

2 Assignments

Timeline View

Assignment View

Litigations

0 Petitions

Accused Products

Abstract

An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.

205 Citations

45 Claims

1. An orally disintegrable tablet which comprises(i) fine granules having an average particle diameter of 400 μ
- m or less, which fine granules comprise a composition coated by an enteric coating layer comprising a first component which is an enteric coating agent and a second component which is a sustained-release agent, said composition having 10 weight % or more of an acid-labile physiologically active substrate that is lansoprazole and (ii) an additive wherein said tablet having a hardness strength of about 1 to about 20 kg, is orally disintegrable.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)
- - 2. An orally disintegrable tablet of claim 1, wherein the average particle diameter of the fine granule is 300 to 400 μ
    - m.
  - 3. An orally disintegrable tablet of claim 1, wherein the fine granules further comprise a basic inorganic salt.
  - 4. An orally disintegrable tablet of claim 1, wherein the additive comprises a water-soluble sugar alcohol.
  - 5. An orally disintegrable tablet of claim 1, wherein the composition coated by an enteric coating layer is further coated by a coating layer which comprises a water-soluble sugar alcohol.
  - 6. An orally disintegrable tablet of claim 4, wherein the additive comprises (1) crystalline cellulose and/or (ii) low-substituted hydroxypropyl cellulose.
  - 7. An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine granules is practically 425 μ
    - m or less.
  - 8. An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine granules is practically 400 μ
    - m or less.
  - 9. An orally disintegrable tablet of claim 3, wherein the basic inorganic salt is a salt of magnesium and/or a salt of calcium.
  - 10. An orally disintegrable tablet of claim 1, wherein the composition comprises a core being coated by a benzimidazole compound and a basic inorganic salt, said core comprising crystalline cellulose and lactose.
  - 11. An orally disintegrable tablet of claim 10, wherein the core comprises 50 weight % or more of lactose.
  - 12. An orally disintegrable tablet of claim 10, wherein the core comprises 40 to 50 weight % of crystalline cellulose and 50 to 60 weight % of lactose.
  - 13. An orally disintegrable tablet of claim 1, wherein the composition comprises 20 weight % or more of an acid-labile physiologically active substance.
  - 14. An orally disintegrable tablet of claim 1, wherein the composition comprises 20 to 50 weight % of an acid-labile physiologically active substance.
  - 15. An orally disintegrable tablet of claim 1, wherein the fine granules are produced by fluidized-bed granulation method.
  - 16. An orally disintegrable tablet of claim 1, wherein the enteric coating layer comprises an aqueous enteric polymer agent.
  - 17. An orally disintegrable tablet of claim 16, wherein the aqueous enteric polymer agent is a methacrylate copolymer.
  - 18. An orally disintegrable tablet of claim 1, wherein the sustained-release agent is a methacrylate copolymer.
  - 19. An orally disintegrable tablet of claim 16, wherein the sustained-release agent is in an amount of 5 15 weight % relative to 100 weight % of the aqueous enteric polymer agent.
  - 20. An orally disintegrable tablet of claim 4, wherein the water-soluble sugar alcohol is erythritol.
  - 21. An orally disintegrable tablet of claim 4, wherein the water-soluble sugar alcohol si mannitol.
  - 22. An orally disintegrable tablet of claim 5, wherein the water-soluble sugar alcohol is in an amount of 5 to 97 weight % relative to 100 weight % of the orally disintegrable tablet apart from the fine granules.
  - 23. An orally disintegrable tablet of claim 4, wherein the crystalline cellulose is in an amount of 3 to 50 weight % relative to 100 weight % of the tablet apart from the fine granule.
  - 24. An orally disentegrable tablet of claim 6, wherein the content of hydroxypropoxyl group in the low-substituted hydroxypropyl cellulose is 7.0 to 9.9 weight %.
  - 25. An orally disintegrable tablet of claim 6, wherein the content of hydroxypropoxyl group in the low-substituted hydroxypropoxyl cellulose is 5.0 7.0 weight %.
  - 26. An orally disintegrable tablet of claim 1, which further comprises crosprovidone.
  - 27. An orally disintegrable tablet of claim 1, wherein the oral disintegration time is one minute or less.
  - 28. An orally disintegrable tablet of claim 1, which comprises no lubricant inside the tablet.
  - 30. Fine granules of claim 28, wherein the average particle diameter of the fine granules is 300 to 400 μ
    - m.
  - 31. Fine granules of claim 28, wherein the particle diameter of the fine granules is practically 425 μ
    - m or less.
  - 32. Fine granules of claim 28, wherein the particle diameter of the fine granules is practically 400 μ
    - m or less.
  - 33. Fine granules of claim 28, wherein the basic inorganic salt is a salt of magnesium and/or a salt of calcium.
  - 34. Fine granules of claim 28, wherein the composition comprises a core being coated by a benzimidazole compound and a basic inorganic salt, said core comprising crystalline cellulose and lactose.
  - 35. Fine granules of claim 34, wherein the core comprises 50 weight % or more of lactose.
  - 36. Fine granules of claim 28, wherein the composition comprises 25 to 40 weight % of an acid-labile physiologically active substance.
  - 37. Fine granules of claim 28, which are produced by fluidized-bed granulation method.
  - 38. Fine granules of claim 28, wherein the enteric coating layer comprises an aqueous enteric polymer agent.
  - 39. Fine granules of claim 38, wherein the aqueous enteric polymer agent is a methacrylate copolymer.
  - 40. Fine granules of claim 28, wherien the sustained-release agent is a methacrylate copolymer.
  - 41. Fine granules of claim 28, wherein the sustained-release agent is in an amount of 5 to 15 weight % relative to 100 weight % of the aqueous enteric polymer agent.
  - 42. Fine granules of claim 28, wherein the enteric coating layer is in an amount of 50 to 70 weight % relative to 100 weight % of the fine granules.
  - 43. A tablet, granule, fine granule, capsule, effervescent or suspension preparation which comprises the fine granules of claim 28.
  - 44. An orally disintegrable tablet of claim 16, wherein the sustained-release agent is in an amount of 5 to 30 weight % relative to 100 weight % of the aqueous enteric polymer agent.
  - 45. Fine granules of claim 38, wherein the sustained-release agent is in an amount of 5 to 30% relative to 100 weight % of the aqueous enteric polymer agent.

29. Fine granules having an average particle diameter of 400 μ
- m or less, which comprise a composition coated by an enteric coating layer comprising a first component which is an enteric coating agent and a second component which is a sustained-release agent, said composition having (i) 25 weight % or more of an acid-liable physiologically active substance that is lansoprazole and (ii) a basic inorganic salt.

Specification

Resources

Litigation Campaign Assessment

Litigation Data

Current Assignee
Takeda Pharmaceutical Company Limited
Original Assignee
Takeda Chemical Industries, Ltd. (Takeda Pharmaceutical Company Limited)
Inventors
Tabata, Tetsuro, Morimoto, Shuji, Shimizu, Toshihiro
Primary Examiner(s)
Page, Thurman K.
Assistant Examiner(s)
TRAN, SUSAN T

Application Number

US09/355,781
Time in Patent Office

860 Days
Field of Search

424/464, 424/465, 424/466, 424/489, 424/490, 424/493
US Class Current

424/489
CPC Class Codes

A61K 31/4439   containing a five-membered ...

A61K 9/0056   Mouth soluble or dispersibl...

A61K 9/1611   Inorganic compounds

A61K 9/1652   Polysaccharides, e.g. algin...

A61K 9/2081   with microcapsules or coate...

A61K 9/28   Dragees; Coated pills or ta...

A61K 9/5026   obtained by reactions only ...

A61K 9/5042   Cellulose; Cellulose deriva...

A61K 9/5073   having two or more differen...

A61P 1/04   for ulcers, gastritis or re...

A61P 43/00   Drugs for specific purposes...

Orally disintegrable tablets

First Claim

2 Assignments

Litigations

0 Petitions

Accused Products

Abstract

205 Citations

45 Claims

Specification

Solutions

Use Cases

Quick Links

Orally disintegrable tablets

First Claim

2 Assignments

Subscription Required

Subscription Required

Litigations

0 Petitions

Subscription Required

Accused Products

Subscription Required

Abstract

205 Citations

45 Claims

Specification

Subscription Required

Solutions

Use Cases

Quick Links